PREVENT IV: Treatment of coronary vein grafts with CGT003 in patients undergoing CABG

Study of:
Drug - E3F Decoy, CGT003

Subjects undergoing coronary artery bypass surgery have a saphenous vein removed from their leg to be sewn onto the heart to bypass blockages of flow. In this study, that vein is treated with the study drug or with placebo before it is sewn onto the heart. The purpose of this study is to determine the efficacy of graft pretreatment with the study drug (E3F Decoy, CGT003) as compared to placebo. Occurrence of major adverse cardiac events, myocardial infarction and/or the need for revascularization due to graft failure at five years are evaluated.

Follow-up telephone calls are conducted at one, six and nine months, and the first 2400 patients enrolled in the study undergo coronary angiography at one year to assess graft patency. Prevent IV is closed to enrollment at this time.

Timothy J. Kroshus, MD, PhD

Dave Chose, RN

For more information about this study or the Cardiovascular Surgery Research program at the Minneapolis Heart Institute Foundation, please contact Dave Chose, RN, CCRC at 612.863.3834.